NCT04295005View on ClinicalTrials.gov

A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists

CompletedOBSERVATIONAL
Enrollment

24,500

Participants

Timeline

Start Date

November 16, 2020

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2021

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Empagliflozin

film coated tablet

DRUG

DPP-4i

film coated tablets, specifically Sitagliptin

DRUG

GLP-1-RA

subcutaneous injection or tablet

Trial Locations (1)

55216

Boehringer Ingelheim, Ingelheim

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT04295005 - A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists | Biotech Hunter | Biotech Hunter